Xencor, Inc. $XNCR Shares Bought by Erste Asset Management GmbH

Erste Asset Management GmbH raised its position in Xencor, Inc. (NASDAQ:XNCR) by 26.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 480,200 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the period. Erste Asset Management GmbH owned about 0.67% of Xencor worth $7,347,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Hantz Financial Services Inc. grew its holdings in Xencor by 209.1% in the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,156 shares during the last quarter. Federated Hermes Inc. grew its holdings in Xencor by 114.3% in the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 2,105 shares during the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in Xencor in the fourth quarter valued at $81,000. Tower Research Capital LLC TRC grew its holdings in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 3,018 shares during the last quarter. Finally, E Fund Management Co. Ltd. acquired a new stake in Xencor in the second quarter valued at $79,000.

Analyst Ratings Changes

Several analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a report on Friday, March 27th. Wall Street Zen lowered Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. Zacks Research lowered Xencor from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. increased their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Finally, Barclays increased their price objective on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $24.50.

Xencor Trading Down 3.1%

NASDAQ XNCR opened at $11.41 on Tuesday. The business’s 50-day moving average price is $12.11 and its 200 day moving average price is $13.20. Xencor, Inc. has a twelve month low of $6.92 and a twelve month high of $18.69. The company has a market capitalization of $845.94 million, a PE ratio of -4.98 and a beta of 0.92.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The business had revenue of $4.52 million for the quarter, compared to analysts’ expectations of $27.86 million. During the same quarter last year, the company posted ($0.66) earnings per share. The business’s quarterly revenue was down 86.2% compared to the same quarter last year. Equities analysts predict that Xencor, Inc. will post -3.84 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.